BRIEF published on 08/27/2024 at 13:05, 2 years ago Pharnext begins liquidation proceedings Creditors Liquidation Paris Commercial Court Pharnext Suspension Of Listing
BRIEF published on 08/27/2024 at 13:05, 2 years ago Pharnext entame une procédure de liquidation judiciaire Liquidation Judiciaire Tribunal De Commerce De Paris Suspension De Cotation Pharnext Créditeurs
PRESS RELEASE published on 08/27/2024 at 13:00, 2 years ago Ouverture d'une procédure de liquidation judiciaire Pharnext SCA, société biopharmaceutique en liquidation judiciaire après procédure de conciliation. Suspension de la cotation des actions Biopharmaceutique Liquidation Judiciaire Suspension Cotation Pharnext Procédure Conciliation
BRIEF published on 07/04/2024 at 20:05, 2 years 2 months ago Pharnext announces the termination of the financing contract granted by Néovacs Investors Termination Funding Pharnext Néovacs
BRIEF published on 07/04/2024 at 20:05, 2 years 2 months ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Financement Investisseurs Pharnext Résiliation Néovacs
PRESS RELEASE published on 07/04/2024 at 20:00, 2 years 2 months ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Pharnext annonce la résiliation anticipée du contrat de financement avec Néovacs suite à des cas de défaut. La société sollicite Global Tech Opportunities 13 pour son soutien Financement Pharnext Résiliation Néovacs Global Tech Opportunities
BRIEF published on 06/18/2024 at 18:35, 2 years 2 months ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext Procédure De Conciliation CMT1A PXT3003 Tasly
BRIEF published on 06/18/2024 at 18:35, 2 years 2 months ago Pharnext announces the extension of the conciliation procedure until July 15, 2024 Pharnext Conciliation Procedure CMT1A PXT3003 Tasly
PRESS RELEASE published on 06/18/2024 at 18:30, 2 years 2 months ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 pour poursuivre l'étude clinique de Phase III de PXT3003. Les résultats seront communiqués prochainement Conciliation Étude Clinique Pharnext PXT3003 Maladie Neurodégénérative
BRIEF published on 05/07/2024 at 19:15, 2 years 4 months ago Adjustment of the nominal value at Pharnext Biopharmaceutical Capital Reduction Pharnext Nominal Value Neurodegenerative Diseases
Published on 09/11/2026 at 23:00, 1 hour 6 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 2 hours 1 minute ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 2 hours 41 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 7 hours 6 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 17:00, 7 hours 6 minutes ago Critical Elements sélectionné pour inclusion dans le prospectus du sommet Canadien de l'investissement, mettant le projet en valeur auprès d'investisseurs mondiaux de premier plan
Published on 09/11/2026 at 22:15, 1 hour 51 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 hour 55 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 4 hours 21 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 5 hours 50 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 17 hours 6 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 17 hours 6 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 17 hours 6 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 4 hours ago Availability of the 2026 Interim Financial Report
